Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesTiziana Life Sciences Ltd

Tiziana Life Sciences Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.621 USD 0.01 ( 1.77%)
Last update at 2026-11-11T21:00:00Z
VOLUME
357811
Market Cap
93.29M

Momentum Score

…

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.61
Low
0.66
High
52 Week Price Range
0.41
Low
1.27
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Tiziana Life Sciences is a clinical-stage biotechnology company developing therapeutics in immunology and oncology with multiple clinical and preclinical programs. Long-term growth could be supported by successful clinical results, regulatory milestones and licensing or partnership agreements, and investors may view exposure to a focused pipeline addressing unmet medical needs as an attractive high-risk, high-reward opportunity.

Principal risks include high clinical and regulatory uncertainty, significant cash burn with likely need for additional financing and potential shareholder dilution, and typical small-cap operational and liquidity risks.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.61
Dividend Yield
-
Revenue TTM
-3.60M
Revenue Per Share
-0.02
Gross Profit TTM
0.00M
Debt / Equity
0.04
ROE
-140.93%
Net Debt
-0.94M
ROCE
-258.39%
Diluted EPS TTM
-0.19

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -15.40M -26.66M -30.07M -10.29M -9.46M
Minority interest - - - - 0.00M
Net income -16.21M -23.42M -27.73M -9.58M -7.61M
Selling general administrative 1.63M 0.85M 14.02M 6.21M 4.42M
Gross profit - 0.00M 0.00M 0.00M 0.00M
Reconciled depreciation 0.05M 0.14M 0.09M 0.20M 0.01M
Ebit -14.59M -27.37M -29.74M -10.19M -9.45M
Ebitda -15.34M -26.34M -32.17M -9.93M -9.43M
Depreciation and amortization -0.75M 1.03M -2.43M 0.26M 0.02M
Non operating income net other - - - - 0.00M
Operating income -14.59M -27.37M -29.74M -10.19M -9.45M
Other operating expenses 14.59M 27.37M 32.27M 10.19M 9.45M
Interest expense 0.01M 0.18M 0.34M 0.09M 0.01M
Tax provision 0.00M -3.24M -2.21M -0.54M -1.53M
Interest income 0.00M 0.00M 0.01M 0.00M 0.01M
Net interest income -0.01M -0.18M -0.31M -0.07M -0.01M
Extraordinary items - - - - 0.00M
Non recurring - - - - 0.00M
Other items - - - - 0.00M
Income tax expense 0.81M -3.24M -2.34M -0.71M -1.85M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 14.59M 27.37M 32.27M 10.19M 9.45M
Cost of revenue - 0.00M 0.00M 0.00M 0.00M
Total other income expense net -0.81M 0.72M -0.33M -0.09M -0.01M
Discontinued operations - - - - 0.00M
Net income from continuing ops -15.40M -23.42M -26.13M -7.31M -6.30M
Net income applicable to common shares -15.40M -23.42M -26.13M -9.32M -7.93M
Preferred stock and other adjustments - - - - 0.00M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 12.18M 26.48M 48.83M 70.55M 2.37M
Intangible assets - - 0.13M 0.10M -
Other current assets - 6.16M 6.49M 0.00M 1.30M
Total liab 6.65M 6.91M 7.55M 8.25M 7.85M
Total stockholder equity 5.54M 19.57M 41.28M 62.29M -5.48M
Other current liab 0.01M 1.58M 3.14M 0.08M 0.08M
Common stock 0.10M 0.10M 0.10M 7.96M 5.37M
Capital stock 0.10M 0.10M 0.10M 7.96M 5.37M
Retained earnings -133.68M -116.26M -108.06M -84.92M -56.57M
Other assets - - - 0.12M 0.43M
Cash 1.18M 18.12M 42.19M 65.71M 0.20M
Total current liabilities 6.54M 6.66M 7.55M 7.97M 7.31M
Current deferred revenue 2.25M - - 4.25M 0.59M
Net debt -0.94M -17.76M -42.19M -65.16M 0.62M
Short term debt 0.14M 0.12M - 0.27M 0.28M
Short long term debt total 0.25M 0.36M - 0.55M 0.82M
Other stockholder equity 22.05M 20.16M 30.09M 177.53M 45.72M
Property plant equipment - 0.39M 0.02M 0.36M 0.44M
Total current assets 7.34M 24.28M 48.68M 70.06M 1.50M
Long term investments 4.55M 1.81M - - -
Net tangible assets - 19.57M 41.15M 62.39M -5.51M
Net receivables 6.05M 5.99M 5.31M 3.78M 1.28M
Inventory - -5.99M -5.31M 0.56M -
Accounts payable 4.14M 4.96M 4.41M 3.36M 6.36M
Accumulated other comprehensive income 117.06M 115.57M 119.15M -38.27M -0.04M
Common stock total equity - - - 10.79M 4.10M
Non currrent assets other - - 0.13M 0.12M 0.43M
Non current assets total 4.85M 2.19M 0.15M 0.49M 0.87M
Capital lease obligations 0.25M 0.36M 0.00M 0.56M 0.62M
Long term debt total - - - - 0.41M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -4.00M 0.13M -0.12M -0.00M 0.00M
Change to liabilities -1.35M -0.69M 1.15M 0.44M 0.14M
Total cashflows from investing activities -2.68M 0.13M -0.12M -0.00M -0.00M
Net borrowings -0.06M -0.15M -0.11M 1.68M 1.68M
Total cash from financing activities -0.06M -0.02M 78.31M 1.73M 9.55M
Change to operating activities 1.35M -0.77M -1.41M 0.14M 1.80M
Net income -15.40M -26.66M -30.07M -10.29M -9.46M
Change in cash -24.06M -23.64M 65.50M -5.26M 5.22M
Begin period cash flow 42.19M 65.82M 0.21M 5.46M 0.06M
End period cash flow 18.12M 42.19M 65.71M 0.20M 5.28M
Total cash from operating activities -19.61M -21.76M -12.67M -6.98M -4.33M
Issuance of capital stock 0.00M 0.00M 82.71M 1.93M 11.43M
Depreciation 0.05M 0.14M 0.10M 0.26M 0.02M
Other cashflows from investing activities - 0.15M 0.15M 0.15M 0.15M
Dividends paid - - - - 0.00M
Change to inventory - - - - 0.00M
Change to account receivables -1.16M -0.09M -0.03M -0.29M -1.54M
Sale purchase of stock - - - 1.47M 8.57M
Other cashflows from financing activities -4.00M 0.13M 0.54M -0.21M -1.32M
Change to netincome -3.10M 2.29M 15.00M 1.99M 1.37M
Capital expenditures 0.00M 0.02M 0.13M 0.00M 0.00M
Change receivables - - - - 0.00M
Cash flows other operating - - - - 0.00M
Exchange rate changes - - - - 0.00M
Cash and cash equivalents changes - - - - 0.00M
Change in working capital -1.16M -0.77M -0.31M 0.30M 1.85M
Stock based compensation -1.41M 5.17M 5.12M 1.30M 0.80M
Other non cash items -1.70M 0.87M 14.77M 0.16M 0.08M
Free cash flow -19.61M -21.78M -12.81M -6.99M -4.33M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
TLSA
Tiziana Life Sciences Ltd		 0.01
1.77%		 0.62 - - - 3.32 -1.95
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

14/15 Conduit Street, London, United Kingdom, W1S 2XJ

44 20 7495 2379

https://www.tizianalifesciences.com

Name Title Year Born
Mr. Gabriele Marco Antonio Cerrone M.B.A., MBA Founder, Exec. Chairman & Interim CEO 1972
Dr. Andrea Brancale Scientific Founder NA
Mr. Richard Clarkson Ph.D. Scientific Founder NA
Mr. Andrew Westwell Ph.D. Scientific Founder NA
Ms. Keeren Shah Chief Financial Officer 1977
Dr. Matthew W. Davis M.D., RPh Chief Medical Officer & Acting Chief Scientific Officer NA
Prof. Napoleone Ferrara M.D. Member of Scientific Advisory Board 1957
Prof. Roberto Pellicciari Ph.D. Consultant NA
Mr. Gabriele Marco Antonio Cerrone M.B.A. Founder, Executive Chairman & Interim CEO 1972
Ms. Keeren Shah Chief Financial Officer 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…